Market Intelligence, Clinical Progress, and High-Purity Reagents for Proteasome-Related Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PSMD3 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMD3 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI and binding assays. |
View PSMD3 Products |
| Gene Delivery | PSMD3 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression rescue assays. |
View PSMD3 Products |
| Benchmark Ab | Anti-PSMD3 Recombinant Antibody High-specificity positive control for Western Blot, ELISA, and IP validation. |
View PSMD3 Products |
| Validator | PSMD3 siRNA Set Target-specific knockdown verification to confirm phenotype-to-target specificity. |
View PSMD3 Products |
| Related Target A | ERBB2 Co-amplified with PSMD3 on chromosome 17q21; synergistic driver in HER2+ breast cancers. |
View ERBB2 Products |
| Related Target B | PSMD1 Direct structural partner within the 19S proteasome regulatory particle. |
View PSMD1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-protein complex aggregation | Monomeric, sequence-verified PSMD3 recombinant proteins with optimized solubility tags. |
| Epitope shielding in cell-based assays | Lentivirus-mediated stable expression preserving native conformation and subunit assembly. |
| Lack of Controls | Validated clinical-grade benchmark antibodies and siRNA sets included for phenotypic controls. |
| False Positives | High-purity, endotoxin-controlled proteins prevent non-specific immune activation in cell assays. |
Live PSMD3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for proteasome-modulating therapeutics is diversifying beyond the catalytic 20S core. Major players are shifting focus from systemic proteasome inhibitors to regulatory subunit targets like PSMD3 (a non-ATPase subunit of the 19S regulator) to bypass the dose-limiting toxicities of first-generation agents. As targeted protein degradation (TPD) and molecular glues reach clinical maturity, the next wave of R&D is targeting PSMD3 to disrupt oncogenic scaffolding and selectively destabilize client proteins like HER2 and E2F1 in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Molecular Glue | Arvinas, Monte Rosa Therapeutics | HER2+ Breast Cancer, Inflammatory Breast Cancer | Ternary Complex Assay (Need high-purity recombinant PSMD3 and partner proteins) |
| Small Molecule PPI Inhibitor | Academic Consortia, Biotech Startups | Lung Adenocarcinoma, Colorectal Cancer | Binding Affinity & Stability Assays (Need sequence-verified monomeric protein) |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Refractory Solid Tumors | In vitro Knockdown Validation (Need validated siRNA and Lentivirus controls) |